Literature DB >> 6340504

Controlled comparison of gentamicin and tobramycin nephrotoxicity.

G R Matzke, R L Lucarotti, H S Shapiro.   

Abstract

317 patients with suspected or documented infections other than cystitis were randomly assigned to receive gentamicin or tobramycin dosed according to the Sawchuk/Zaske method or a modification of the McHenry method. 196 patients completed 6 days of therapy, had serial determinations of serum creatinine and were evaluated for nephrotoxicity. Within each dosing method group those patients receiving gentamicin and tobramycin had a similar mean age, initial serum creatinine level, total dose, duration of therapy and trough serum aminoglycoside concentration. Nephrotoxicity developed in 5 of 49 (10.2%) given gentamicin via the McHenry method compared to 9 of 49 (18.4%) given tobramycin. Similarily, 4 of 50 (8.0%) given gentamicin via the Sawchuk/Zaske method developed nephrotoxicity compared to 8 of 48 (16.7%) given tobramycin. Within the Sawchuk/Zaske and the modified McHenry dosing method groups, no significant difference was noted in the incidence of nephrotoxicity associated with gentamicin and tobramycin. 34% of patients with elevated trough serum aminoglycoside concentrations developed nephrotoxicity compared to 3.7% of those with nonelevated troughs (p less than 0.0005).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6340504     DOI: 10.1159/000166680

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  11 in total

1.  Evaluating IV drug delivery systems.

Authors:  J Garrelts
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 2.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Pharmacokinetic and nephrotoxic study of gentamicin in rabbits using a new dosage regimen.

Authors:  M A Trapote; M A Arévalo; J M Lanao; M G Macias; A S Navarro; M J Alonso; M L Sayalero; A Domínguez-Gil
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Apr-Jun       Impact factor: 2.441

Review 4.  Methods of minimising the cost of aminoglycoside therapy to hospitals.

Authors:  C A Gentry; K A Rodvold; J S Bertino
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 5.  Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring.

Authors:  R L Slaughter; D M Cappelletty
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

Review 6.  An updated comparison of drug dosing methods. Part III: Aminoglycoside antibiotics.

Authors:  S M Erdman; K A Rodvold; R D Pryka
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 7.  Cost considerations in therapeutic drug monitoring of aminoglycosides.

Authors:  J S Bertino; K A Rodvold; C J Destache
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

8.  Long-term protection of polyaspartic acid in experimental gentamicin nephrotoxicity.

Authors:  S K Swan; S J Kohlhepp; P W Kohnen; D N Gilbert; W M Bennett
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

Review 9.  The role of medications and their management in acute kidney injury.

Authors:  Bradford L McDaniel; Michael L Bentley
Journal:  Integr Pharm Res Pract       Date:  2015-05-18

10.  A review on therapeutic drug monitoring of immunosuppressant drugs.

Authors:  Niloufar Mohammadpour; Sepideh Elyasi; Naser Vahdati; Amir Hooshang Mohammadpour; Jamal Shamsara
Journal:  Iran J Basic Med Sci       Date:  2011-11       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.